ArticleFrontiers in oncology2026
Distribution of molecular subtypes in a Colombian cohort of patients with acute lymphoblastic leukemia using whole-transcriptome analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute lymphoblastic leukemia (ALL) is a common pediatric malignancy and shows marked genetic heterogeneity. Transcriptomic profiling may improve molecular diagnosis and risk stratification, particularly in admixed Latin American populations. Methods: We characterized the transcriptomic landscape of pediatric ALL in 40 Colombian patients aged <20 years using whole-transcriptome RNA sequencing of diagnostic bone marrow or peripheral blood samples. Bioinformatic analyses enabled molecular subtype assignment, fusion detection, differential expression analysis, and variant calling. Results: The median age was 8 years, and 8 patients had measurable residual disease at the end of induction. The most frequent subtypes were Conclusions: Molecular classification refined conventional risk stratification in 10% of patients, supporting the potential clinical utility of transcriptomic profiling in pediatric ALL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.